KLK3 and prostate cancer: The Capio PCC model demonstrated a notable 43% reduction in MRI indications compared with PSA ≥ 3 ng/ml when using Stockholm3 ≥ 15, showcasing its efficacy in optimizing prostate cancer diagnostics.